This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Moderna (MRNA) Up on Its COVID Vaccine's Receipt of Full FDA Nod
by Zacks Equity Research
The FDA grants full approval to Moderna's (MRNA) mRNA-based COVID-19 vaccine, Spikevax, for individuals aged 18 years and above. Shares up.
Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.
Novavax's (NVAX) Shares Rise on FDA Filing for COVID Jab
by Zacks Equity Research
After a series of delays, Novavax (NVAX) finally files a regulatory application with the FDA seeking emergency use authorization of its COVID-19 vaccine.
Pfizer (PFE) Ends Vupanorsen Development, Returns Rights to Ionis
by Zacks Equity Research
Pfizer (PFE) returns development rights to Ionis for the investigational antisense therapy, vupanorsen.
Will Merck (MRK) Succeed in Beating Q4 Earnings Expectations?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q4 earnings.
Best Growth Stocks to Buy for February 1st
by Zacks Equity Research
CROX, TOL, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 1, 2022
Novavax (NVAX) Stock Rises on Deal for COVID-19 Jab in Israel
by Zacks Equity Research
Novavax (NVAX) enters into a supply agreement for its COVID-19 vaccine candidate, NVX-CoV2373, with Israel's Ministry of Health. Shares rise.
Bristol-Myers (BMY) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Bristol-Myers' (BMY) Q4 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped on costs associated with the broader portfolio.
Pfizer (PFE) Lorviqua Gets EU Nod for First-Line Lung Cancer
by Zacks Equity Research
The European Commission approves label expansion of Pfizer's (PFE) Lorviqua as a first-line treatment for ALK-positive non-small cell lung cancer.
Lilly (LLY) Stops Lupus Study, Expects CRL for Olumiant in Eczema
by Zacks Equity Research
While Eli Lilly (LLY) and Incyte (INCY) have decided to discontinue the development of JAK inhibitor Olumiant in lupus indication, they expect a complete response letter from the FDA for Olumiant in atopic dermatitis.
AbbVie's (ABBV) Q4 Earnings May Reflect Slower Sales Recovery
by Zacks Equity Research
AbbVie's (ABBV) drugs are expected to have continued the recovering trend in sales during the fourth quarter. However, increased COVID-19 cases are likely to have hurt the pace of recovery during the quarter.
Will Eylea, Dupixent Aid Regeneron's (REGN) Q4 Earnings?
by Zacks Equity Research
Regeneron's (REGN) fourth-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.
Best Growth Stocks to Buy for January 31st
by Zacks Equity Research
PFE, TOL, and M made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 31, 2022
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and J&J
by Zacks Equity Research
Pfizer, BioNTech, Moderna and J&J are included in this analyst blog.
Pfizer (PFE) Gets CHMP Recommendation for COVID Pill Paxlovid
by Zacks Equity Research
Pfizer's (PFE) oral COVID-19 drug, Paxlovid, gets recommendation from the CHMP for its authorization in Europe for treating mild-to-moderate COVID-19 in patients at increased risk of hospitalizations.
Merck (MRK) Keytruda Gets EU Nod for Expanded Kidney Cancer Use
by Zacks Equity Research
Following EU nod, Merck's (MRK) Keytruda is now approved as an adjuvant therapy for renal cell carcinoma in certain adult patients who are at an increased risk of recurrence, following nephrectomy.
Gilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) fourth-quarter 2021 results.
Pharma Stock Roundup: J&J Q4 Earnings, FDA's Rejection of PFE, MRK Pipeline Drugs
by Kinjel Shah
J&J (JNJ) reports mixed fourth-quarter results. FDA issues CRL to Merck (MRK) and Pfizer's (PFE) pipeline candidates. FDA approves AbbVie's (ABBV) Skyrizi for a second indication.
Best Growth Stocks to Buy for January 28th
by Zacks Equity Research
CROX, M, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 28, 2022
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
Pfizer (PFE), BioNTech Begin Omicron-Based COVID-19 Jab Study
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) announce that the first participants in a clinical study on its Omicron-specific COVID-19 vaccine candidate have been dosed.
Moderna (MRNA) Starts Study for Omicron-Specific Booster Jab
by Zacks Equity Research
Moderna (MRNA) doses the first participant in a phase II study on its Omicron specific COVID-19 booster candidate in a mid-stage study.
Best Growth Stocks to Buy for January 27th
by Zacks Equity Research
TOL, PFE, and M made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 27, 2022
Moderna's (MRNA) Investors Losing Wealth: What Lies Ahead?
by Zacks Equity Research
Moderna's (MRNA) stock has been on a declining trend since August 2021 after a strong rally since the beginning of 2020.
The Zacks Analyst Blog Highlights: Mastercard Inc., Pfizer Inc. and Citigroup Inc
by Zacks Equity Research
Mastercard Inc., Pfizer Inc. and Citigroup Inc are included in this blog.